One in 4 Americans> 40 years of age takes a statin to reduce the risk of myocardial
infarction, ischemic stroke, and other complications of atherosclerotic disease. The most …

The HMG-CoA reductase inhibitors (statins) are effective in both the primary and secondary
prevention of ischaemic heart disease. As a group, these drugs are well tolerated apart from …

Emerging data suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) offer important benefits for the large population of individuals at …

'2005 CMA Media Inc. Can J Surg, Vol. 48, No. 4, August 2005 319 terial intima that
develops in both the epicardial and intramyocardial arteries of the transplanted heart. The …

Since their introduction for the treatment of hypercholesterolaemia in 1987, the use of statins
has grown to over 100 million prescriptions per year. 1 About 1.5-3% of statin users in …

BACKGROUND: Outcomes from this trial's first year data demonstrated significant benefit in
heart transplant patients treated with pravastatin in cholesterol levels, survival, rejection with …

Cardiovascular disease is a major cause of graft loss and the leading cause of death in
renal transplant recipients. Although there are robust data on the frequency of risk factors …

O transplante cardíaco persiste sendo o tratamento de escolha para a insuficiência cardíaca
refratária, apesar da grande melhora na expectativa de vida com o tratamento clínico …

Lipid abnormalities are present in 60% to 81% of heart transplant recipients. 28–30
Hyperlipidemia is thought to play a role in the development of CAV, cerebrovascular …

Objectives: We sought to evaluate the relative effects of low doses of pravastatin (20 mg/day)
and simvastatin (10 mg/day) on indices of cardiac allograft rejection. We further examined …